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TUMOR RESISTANCE EXPLAINED BY HORMESIS

Edward J. Calabrese, Ph.D. 䊐 Department of Public Health, Environmental
Health Sciences, University of Massachusetts, Amherst, MA 01003
Marc A. Nascarella, Ph.D.

䊐

Gradient, Cambridge, MA 02138

䊐 Enhanced drug (GDC 0449) resistance in a mouse model for human medulloblastoma
is shown in the present paper to act via an hormetic response. This has significant implications, imposing constraints on the quantitative features of the dose response of the
chemotherapeutic agent, affecting optimal study design, mechanism assessment strategy,
potential for tumor rebound, patient relapse and disease outcome.
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Yauch et al. (2009) provide evidence of a missense mutation that confers drug resistance to medulloblastoma in a human patient who exhibited a relapse following initially successful chemotherapy. The patient originally was identified with a mutation encoding the inhibitory receptor
Patched 1 (PTCH1-W844C), that resulted in up-regulation of hedgehog
(Hh) pathway target genes. The patient was orally treated with the Hh
antagonist GDC-0449. PET scans three months after initiation of treatment revealed the disease had progressed. The new neoplastic growth displayed markedly enhanced resistance to GDC-0449. The enhanced resistance was not associated with SMO locus amplification but with a heterozygous G-to-C missense mutation in codon 473 with His replacing Asp.
This mutation was subsequently assessed in an in vivo murine model.
It was referred to as the “corresponding residue” in the human since it is
a mutation in the gene forming the SMO receptor of the Hh pathway,
involving a change in codon from Asp to Gly, similar to that observed in
the patient. The new mouse mutation was associated with a 100-fold
increase in resistance to GDC-0449 based on GLI luciferase activity in
C3H10T1/2 cells transfected with SMO-WT and SMO-D473G cells
derived from allografts from Ptch1+/-, p53-/- mice made resistant to
GDC-0449. At GDC-0449 concentrations below the threshold of toxicity
in both the parent (SMO-WT) and mutated cells (SMO-D473G ) (figure
3C-page 574), a stimulatory response of GLI luciferase activity occurred
in both cell types, an observation not discussed in Yauch et al. (2009). The
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maximum stimulatory response was 130-135% in the newly mutated cells
and 115-118% in the parent cells relative to controls (i.e. 100%). The
stimulatory concentration range exceeded 1000-fold in the newly mutated cells but only about 10-fold in the parental cells. These responses indicate a biphasic hormetic concentration-response for both cell types, but
with a greater magnitude of stimulatory response in the newly mutated
cells based on maximum height and width of the stimulatory response
and area under the curve.
In contrast to the responses seen in the mouse model experiments,
the GDC-0449 had no treatment effect in the newly mutated human cells.
In the parent cells (i.e. initial tumor cells), toxicity was concentration
dependent, starting at the lowest concentration (Figure 2B, Yauch et al.,
2009). Thus, human cells displayed no evidence of hormesis. Since the
newly mutated human cells were not susceptible to the drug while the
parent cells were susceptible at the lowest dose, an evaluation of the
hormesis hypothesis in the human cells was not possible.
These findings indicate that the response of the mouse cells to GDC0449 had some similarity with the human cells (i.e. newly mutated cells
were more resistant in both the human and mouse and were associated
with a similar codon alteration) but nonetheless showed marked quantitative differences, indicating that susceptibility is more complex than can
be explained by the shared corresponding codon residue for the SMO
receptor.
Despite the interspecies variation in responsiveness to GDC-0449 the
observation of hormesis (Calabrese and Baldwin 2001, 2003) is worthy of
further consideration. Hormesis is commonly reported in the pharmacological and toxicological literature (Calabrese and Blain 2005), being
independent of biological model, endpoint, and chemical agent.
Hormesis, a highly conserved strategy by which biological systems adapt
to low level exposures to toxic agents, is a dose response characterized by
a low dose stimulation and high dose inhibition with consistent quantitative features concerning the magnitude and width of the stimulation. The
hormetic response is therefore highly generalizable and extensively
reported within animal and human tumor cell lines (Calabrese 2005;
Calabrese et al. 2006, 2008) including a broad spectrum of brain tumors
(Calabrese 2005). Despite widespread occurrence, hormetic dose
responses are frequently overlooked, most likely because the low-dose
stimulation is modest [30-60% greater than controls; (Calabrese 2008a)],
and similar to the Yauch et al. (2009) study, investigators focus on responses at higher concentrations (e.g. IC50 of therapeutic agents). Since
hormetic dose responses are widespread there are a plethora of mechanisms accounting for specific dose responses across a broad spectrum of
endpoints, including studies with human tumor cell lines. Despite the
diversity of such proximate mechanisms, the quantitative features of the
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hormetic dose responses are similar. This suggests the hormetic dose
response may represent a quantitative estimate of biological plasticity that
is highly generalized.
We suggest the observed increase in resistance as reported by Yauch
et al. (2009) in their mouse model is a manifestation of hormesis. The
enhanced resistance of the mutated mouse cells is observed across the
entire concentration range where there is less inhibition at the higher
concentrations, and larger stimulation at the lower concentrations relative to controls.
By placing constraints on the quantitative features of the biphasic
concentration response, the hormesis model is especially useful for assessing how tumor growth may be stimulated, how the stimulatory response
can be switched to an inhibitory mode, how the stimulatory response can
be constrained, as well as how tumors may rapidly rebound, accelerating
the rate of neoplastic growth and possible relapse. Furthermore, the
hormetic dose response may be useful in illustrating the limits within
which the rebound/relapse effect occurs, significantly affecting subsequent clinical strategies and disease outcome. While this technical
response is focused on the important mutational and experimental findings of Yanch et al. (2009), it should be recognized that the hormetic dose
response is also a central feature in numerous other biomedical endpoints, affecting memory, bone strengthening, wound healing, hair
growth, anxiety, seizure responses, neuroprotection, longevity and
numerous other endpoints critical to patient care and the public health
(Calabrese 2008b).
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